Top Markets
Coin of the day
Chimeric Therapeutics Limited Chimeric Therapeutics Limited

Chimeric Therapeutics Limited

CHM
Rang in aandelen #38385
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical... Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Aandeelprijs
$0.02468497
Marktkapitalisatie
$1.01M
Verandering (1 dag)
-12.50%
Verandering (1 jaar)
-87.34%
Land
AU
Handel Chimeric Therapeutics Limited (CHM)

Categorie

Koersgeschiedenis voor Chimeric Therapeutics Limited (CHM)
Hoogste slotkoers: $0.03 op 2026-08-01

Laagste slotkoers: $25.86 op 2021-01-01
Koersgeschiedenis van Chimeric Therapeutics Limited van 2021 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2026 (TTM) -34.08%
2025 -54.71%
2024 -76.43%
2023 -64.94%
2022 -69.66%
2021 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$505.24 29.45%
US
$846.09 29.68%
NL
$731.69 7.13%
CH
$1.07K -6.40%
KR
$251.82 11.25%
BE